Introduction: As the pharmaceutical advertising landscape evolves with digital advancements, this study examines public awareness and perceptions of medication advertisements in Saudi Arabia. It focuses on the effects of regulatory frameworks and evaluates how they influence public understanding and attitudes toward these advertisements. Method: A cross-sectional study was conducted using an electronic survey in Saudi Arabia in December 2023. The survey was distributed on social media platforms and reached a diverse sample of 440 participants. It covered public perception and attitudes toward drug advertisements, knowledge of regulatory laws, and preferences regarding advertising mediums. Results: Out of the 440 participants in the study, who were primarily employees with bachelor’s degrees, there was a clear awareness of drug advertisements. The average age of the group was 33 years, and a significant portion (71.1%) held a bachelor’s degree, with 51.1% being employed. The findings revealed that 25.5% of participants frequently noticed drug ads, while 22.7% saw them very often. Although many found the ads informative, there were significant concerns about unrealistic expectations and the risk of overmedication; 89.8% believed the ads set unrealistic expectations about the effectiveness of medications. Additionally, 60.7% thought that celebrity endorsements might mislead the audience, and 91.1% felt that ads should provide more detailed information about potential risks and side effects. Regarding preferred advertising platforms, mobile apps and websites were favored (47%), followed closely by social media (46.4%). A striking 93.2% of participants believed that drug ads on social media should be subject to stricter regulations, and 96.4% wanted more proactive monitoring of online advertising. Many also reported using other sources, such as medical review sites, to verify medication information. Conclusions: Pharmaceutical advertising in Saudi Arabia must balance ethical transparency with educational value. The influence of digital platforms underscores the necessity for stricter regulation and accurate information dissemination. A collaborative approach is essential to align advertising practices with public health interests and regulatory standards.

Background: Lipid metabolism disturbances are common in end-stage renal disease (ESRD) patients on hemodialysis (HD), leading to dyslipidemia, which is characterized by abnormal plasma lipids and lipoproteins. Although large randomized controlled trials have generally not demonstrated a survival benefit associated with statin therapy among patients receiving hemodialysis, limited observational studies have reported potential associations with improved clinical outcomes in this population. Methods: This retrospective cohort study investigated the clinical and safety outcomes of statin use in ESRD patients on HD with documented dyslipidemia over a two-year period from 1 January 2018 to 30 December 2019. The primary endpoints evaluated the clinical outcomes of statins by assessing changes in specific lipid parameters, including low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-C). The secondary endpoints assessed safety by monitoring liver enzymes and creatine kinase (CK) levels. Results: Among 179 participants, diabetes mellitus was present in 134 patients (74.9%), while 168 patients (93.9%) had hypertension. Cardiovascular events occurred in 95 patients (53.1%). Statin therapy was administered to 146 patients (82.0%), with atorvastatin being the most frequently prescribed statin (69.3%). Modest reductions in LDL-C levels were observed in the rosuvastatin and atorvastatin groups, whereas slight increases were noted in the simvastatin and non-statin groups. None of these within-group changes were statistically significant. In the atorvastatin group, LDL-C decreased slightly from 2.058 to 2.003 mmol/L. The rosuvastatin group experienced a more pronounced LDL-C reduction from 2.607 to 2.113 mmol/L. Conversely, the simvastatin group showed an LDL-C increase from 1.550 to 1.901 mmol/L. Among the non-statin group, LDL-C increased from 2.678 to 2.820 mmol/L. Liver enzyme and CK levels fluctuated slightly but remained within normal ranges. Conclusions: This study evaluated statin therapy in hemodialysis patients with dyslipidemia. Although modest reductions in LDL-C levels were observed in the atorvastatin and rosuvastatin groups, statin therapy did not reduce the incidence of atherosclerotic events in hemodialysis patients with dyslipidemia. Additionally, statin use was not associated with any clinically or statistically significant effects.

Introduction: Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare and potentially fatal condition primarily affecting patients with end-stage renal disease (ESRD) on hemodialysis (HD). It is characterized by calcification in small blood vessels, leading to painful skin ulcers and high mortality rates. Case Description: This is a case of a 42-year-old female with ESRD on HD who developed calciphylaxis, presenting with non-healing ulcers on her thighs. Discussion: Despite initial treatments, including wound care and pain management, her condition did not improve. A skin biopsy was inconclusive, highlighting the diagnostic challenges associated with calciphylaxis. Based on clinical judgment, warfarin and calcium-based therapies were discontinued, and the patient’s HD regimen was adjusted. Due to the persistence of symptoms, sodium thiosulfate (STS) therapy was initiated, leading to significant improvement in her ulcers after six months of treatment. Conclusions: This case highlights the importance of clinical judgment in the diagnosis and management of calciphylaxis, particularly when histopathological diagnostic methods yield inconclusive results. Clinical criteria, alongside a thorough assessment of the patient’s history and presentation, are vital for achieving a timely diagnosis in such challenging cases. The successful use of sodium thiosulfate in this patient adds to the growing body of evidence supporting its use as a potential treatment for calciphylaxis, especially in cases that do not respond to conventional therapy.

BACKGROUND Herbal medicine is commonly used in Saudi Arabia, and is widely viewed as natural and safe. However, its use among transplant recipients poses risks due to interactions with immunosuppressive therapies. This study explores herbal medicine use, knowledge, and attitudes among Saudi transplant recipients. MATERIAL AND METHODS A cross-sectional study of 203 transplant recipients from multiple clinics in Saudi Arabia was conducted using a structured questionnaire to assess demographics, herbal supplement use, awareness of risks, and attitudes. Statistical analyses compared users and non-users of herbal supplements. RESULTS Post-transplant herbal supplement use decreased significantly (44.3% to 19.2%, p=0.0001). Many relied on unreliable sources like friends or the internet, and 54.24% of reported supplements posed interaction risks with immunosuppressive drugs. Participants aware of these risks were significantly less likely to use herbal supplements (15% vs 88%, p=0.0007). Alarmingly, 81.1% received no pre-transplant education, and 70.4% received no post-transplant care, despite 81% desiring guidance from healthcare providers. CONCLUSIONS Herbal supplement use among transplant recipients in Saudi Arabia is prevalent and risky due to potential drug interactions. Most patients lack education about these risks, underscoring the need for improved healthcare education.

Introduction: Alpinia galanga (L.) rhizome has been widely consumed as a spice and food-flavoring agent and in traditional medicines for the treatment of various diseases such as stomach pain, vomiting, diarrhea, infections, and renal disorders. The clinical use of gentamicin (Genta), an aminoglycoside antibiotic, is constrained due to nephrotoxicity. The existing investigation intended to estimate the mechanistic antioxidant, anti-inflammatory, and anti-apoptotic actions of galangal essential oil (Gal EO) against nephrotoxicity induced by Genta. Materials and Methods: Gal EO was isolated and subjected to GC-MS for analysis. The oil components were in silico investigated against Genta-induced renal toxicity targets using network pharmacology and molecular docking approaches. In vivo studies involved the alienation of rats into four groups. The control and Genta groups rats received 0.5% CMC orally by gavage for 2 weeks and saline or Genta (100 mg/kg) I.P. injection on the 8th to the 14th day. The Genta + Gal EO (50 mg/kg) and Genta + Gal EO (100 mg/kg) groups received Gal EO (50 or 100 mg/kg, P.O.) daily for 2 weeks and Genta (100 mg/kg) I.P. injection. Renal histopathological and kidney function tests, lipid peroxidation, oxidative, inflammatory mediators, and apoptotic markers were assessed. Results: Network Pharmacology suggested Toll-like receptors 4 (TLR4) and interleukin-1beta (IL-1β) as potential targets of Gal EO components in Genta-induced renal toxicity. Gal EO significantly decreased Cr, uric acid, BUN, CysC, NGAL, and Kim-1 levels and the urine albumin/creatinine ratio. Gal EO reduced MDA and NO levels with an upsurge in the GSH content, GPx, GSH-R, catalase, and SOD levels. Gal EO lessened the gene expression of TLR4/MYD88/NF-κB/IL-1β with subsequent reduction in ICAM-1 and MCP-1 expression and the levels of MPO, TNF-α, and IL-6 while intensified IL-10. Gal EO diminished caspase 3, caspase 9, and Bax while amplified Bcl2. Conclusion: Genta-induced nephrotoxicity was mitigated by the anti-inflammatory, antioxidant, and anti-apoptotic effect of Gal EO through decreasing TLR4/MYD88/NF-κB/IL-1β signaling pathway.

Background: Diabetic kidney disease (DKD) represents a significant microvascular complication associated with type 2 diabetes mellitus (T2DM), markedly elevating the risk of kidney failure, cardiovascular events, and premature mortality. Despite advancements in therapeutic management, such as renin–angiotensin–aldosterone system (RAAS) blockade and sodium–glucose cotransporter 2 (SGLT2) inhibitors, residual risk remains significant. Finerenone, a novel nonsteroidal and selective mineralocorticoid receptor antagonist (MRA), has demonstrated substantial cardiorenal benefits in clinical trials; however, real-world data, especially from Saudi Arabia, remain limited. Method: This single-center, retrospective cohort study. All adult patients (≥18 years) who received finerenone as part of routine clinical care were eligible if they met either of the following criteria: (1) documented diabetic kidney disease (DKD) based on KDIGO-aligned clinical criteria, including diabetes mellitus with chronic kidney disease manifested by albuminuria/proteinuria and/or reduced eGFR; (2) and/or a urine protein-to-creatinine ratio (uPCR) >0.3 mg/mg. Longitudinal changes in uPCR, eGFR, and serum potassium were analyzed using linear mixed-effects models adjusted for relevant clinical covariates. Results: A total of 75 patients prescribed finerenone were screened, of whom 67 met the inclusion criteria. The median age was 63 years, and 53.7% were female. Comorbidities were highly prevalent, including diabetes mellitus (89.6%), hypertension (97.0%), dyslipidemia (92.5%), heart failure (56.8%), and coronary artery disease (40.3%). A significant effect of time on uPCR was observed (F[3,193] = 3.457; P = 0.018), with a mean reduction of 0.464 mg/mg after six months (95% CI, −0.895 to −0.034; P = 0.027). The estimated eGFR slope after finerenone initiation was −1.08 mL/min/1.73 m² per month (95% CI −1.74 to −0.41; P = 0.002), corresponding to an annualized decline of approximately −12.9 mL/min/1.73 m² per year. Serum potassium increased modestly at early follow-up points (F[5,245] = 4.008; P = 0.002), rising by +0.209, + 0.256, and +0.286 mmol/L at the first three readings (P = 0.029, 0.005, and 0.006, respectively), then plateaued thereafter (P > 0.5). Conclusion: Finerenone use among DKD patients in Saudi Arabia was associated with significant reductions in proteinuria, an early decline in eGFR that requires cautious interpretation, and an overall favorable safety profile. These real-world findings align with results from pivotal clinical trials and support the incorporation of finerenone into standard DKD management. Future multicenter prospective studies are warranted to confirm these outcomes and evaluate long-term cardiorenal benefits.